Advanced Practical Diagnostics
ActiveSummary
Advanced Practical Diagnostics has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.5m and a net result of €508,322. Equity is growing by ~22.1% per year across the filed fiscal years. Its solvency ranks better than 65% of 50 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability83▲+4
Solvency81▲+9
Growth78=
Track record100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €190,000 at 30 days acceptable
Liquidity ample (current ratio 2.15 against 1.62 in 2024; short-term debt: 26.1% and cash: 4.3% of total assets), and 44.5% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
55.5%
Return on assets
11.3%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 17-07-2026, 14 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
14 d early
2024
25 d late
2023
on the day
2022
18 d early
2021
13 d early
2020
17 d early
2019
2 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 6 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
26-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file What other support did companies like this one receive, and it did not?Subsidy mirror How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
Equity
€2.5m▲ 25.5%
2024 · €2.0m
Total assets
€4.5m▲ 7.0%
2024 · €4.2m
Net result
€508,322▲ 52.8%
2024 · €332,572
Working capital
€1.3m▲ 59.9%
2024 · €843,587
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result€341,537€307,153▼ 10.1%€225,003▼ 26.7%€447,183▲ 98.7%€618,658▲ 38.3%
Net result€296,433€257,724▼ 13.1%€148,306▼ 42.5%€332,572▲ 124%€508,322▲ 52.8%
Equity€1.3m▲ 28.8%€1.5m▲ 14.2%€1.7m▲ 9.8%€2.0m▲ 20.0%€2.5m▲ 25.5%
Total assets€3.6m▲ 1.7%€4.0m▲ 11.4%€4.0m▼ 1.5%€4.2m▲ 5.8%€4.5m▲ 7.0%
Debt€2.3m▼ 9.3%€2.5m▲ 9.8%€2.3m▼ 8.3%€2.2m▼ 4.4%€2.0m▼ 9.7%
Working capital€312,668▲ 94.3%€471,374▲ 50.8%€575,989▲ 22.2%€843,587▲ 46.5%€1.3m▲ 59.9%
Staff (FTE)12.8▼ 8.6%13.2▲ 3.1%13▼ 1.5%13=12.3▼ 5.4%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 38% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €4.5m
Fixed assets
€2.0m ▼ 1.1%
Current assets
€2.5m ▲ 14.3%
Equity and liabilities €4.5m
Equity
€2.5m ▲ 25.5%
Debt
€2.0m ▼ 9.7%
Debt's share of the balance-sheet total falls from 52.7% to 44.5%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€1.0m▲
2024 · €843,809
Cash flow
€915,344▲
2024 · €729,198
Current ratio
2.15▲
2024 · 1.62
Quick ratio
1.33▲
2024 · 0.89
Debt to equity
0.80▼
2024 · 1.11
ROE
20.3%▲
2024 · 16.7%
ROA
11.3%▲
2024 · 7.9%
Interest coverage
17.31▲
2024 · 8.05
Debt ≤ 1 year
€1.2m▼
2024 · €1.4m
Debt > 1 year
€826,058▼
2024 · €851,911
Income taxes
€52,638▲
2024 · €11,204
Staff costs
€1.2m▲
2024 · €1.2m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | €939,441 | €1.2m | €1.1m | €1.2m | €1.2m | ▲ 4.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €394,745 | €449,253 | €523,827 | €396,626 | €407,022 | ▲ 2.6% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | - | €3,628 | - |
| Other operating charges640/8 | €2,872 | €2,798 | €6,339 | €6,532 | €7,238 | ▲ 10.8% |
| Gross operating margin9900 | €1.7m | €1.9m | €1.9m | €2.0m | €2.3m | ▲ 11.8% |
| Operating profit (loss)9901 | €341,537 | €307,153 | €225,003 | €447,183 | €618,658 | ▲ 38.3% |
| Financial income75/76B | €5,491 | €6,638 | €3,612 | €1,460 | €1,545 | ▲ 5.8% |
| Recurring financial income75 | €5,491 | €6,638 | €3,612 | €1,460 | €1,545 | ▲ 5.8% |
| Financial charges65/66B | €49,293 | €54,667 | €78,436 | €104,868 | €59,243 | ▼ 43.5% |
| Recurring financial charges65 | €49,293 | €54,667 | €78,436 | €104,868 | €59,243 | ▼ 43.5% |
| Profit (loss) for the period before taxes9903 | €297,735 | €259,124 | €150,178 | €343,776 | €560,960 | ▲ 63.2% |
| Income taxes67/77 | €1,302 | €1,400 | €1,872 | €11,204 | €52,638 | ▲ 370% |
| Profit (loss) for the period9904 | €296,433 | €257,724 | €148,306 | €332,572 | €508,322 | ▲ 52.8% |
| Profit (loss) for the period to be appropriated9905 | €296,433 | €257,724 | €148,306 | €332,572 | €508,322 | ▲ 52.8% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €3.6m | €4.0m | €4.0m | €4.2m | €4.5m | ▲ 7.0% |
| Fixed assets21/28 | €1.9m | €2.1m | €2.0m | €2.0m | €2.0m | ▼ 1.1% |
| Intangible fixed assets21 | €1.9m | €1.9m | €1.7m | €1.8m | €1.8m | ▲ 2.4% |
| Tangible fixed assets22/27 | €17,833 | €201,878 | €209,909 | €200,400 | €134,845 | ▼ 32.7% |
| Plant, machinery and equipment23 | €11,748 | €37,097 | €65,413 | €67,644 | €46,183 | ▼ 31.7% |
| Furniture and vehicles24 | €6,084 | €3,050 | €17,115 | €39,725 | €29,980 | ▼ 24.5% |
| Leasing and similar rights25 | - | €161,731 | €127,381 | €93,031 | €58,681 | ▼ 36.9% |
| Financial fixed assets28 | €1,448 | €1,448 | €1,448 | €1,430 | €1,430 | = |
| Current assets29/58 | €1.7m | €2.0m | €2.0m | €2.2m | €2.5m | ▲ 14.3% |
| Stocks and contracts in progress3 | €922,051 | €1.0m | €1.0m | €992,597 | €955,387 | ▼ 3.7% |
| Stocks30/36 | €922,051 | €1.0m | €1.0m | €992,597 | €955,387 | ▼ 3.7% |
| Amounts receivable within one year40/41 | €769,481 | €920,895 | €991,052 | €1.2m | €1.3m | ▲ 13.6% |
| Trade receivables40 | €769,035 | €858,441 | €906,059 | €857,495 | €762,483 | ▼ 11.1% |
| Other amounts receivable41 | €446 | €62,454 | €84,993 | €323,269 | €579,252 | ▲ 79.2% |
| Cash at bank and in hand54/58 | €824 | €788 | €2,802 | €23,065 | €193,629 | ▲ 739% |
| Deferred charges and accrued income490/1 | €2,285 | €11,908 | €10,491 | €13,877 | €34,766 | ▲ 151% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €3.6m | €4.0m | €4.0m | €4.2m | €4.5m | ▲ 7.0% |
| Equity10/15 | €1.3m | €1.5m | €1.7m | €2.0m | €2.5m | ▲ 25.5% |
| Contributions10/11 | €1.9m | €1.9m | €1.9m | €1.9m | €1.9m | = |
| Reserves13 | - | - | - | €92,944 | €601,266 | ▲ 547% |
| Distributable reserves133 | - | - | - | €92,944 | €601,266 | ▲ 547% |
| Profit (loss) carried forward14 | -€575,800 | -€387,934 | -€239,628 | €0 | - | - |
| Amounts payable17/49 | €2.3m | €2.5m | €2.3m | €2.2m | €2.0m | ▼ 9.7% |
| Amounts payable after more than one year17 | €924,765 | €1.0m | €876,952 | €851,911 | €826,058 | ▼ 3.0% |
| Financial debts170/4 | €924,765 | €1.0m | €876,952 | €851,911 | €826,058 | ▼ 3.0% |
| Amounts payable within one year42/48 | €1.4m | €1.5m | €1.4m | €1.4m | €1.2m | ▼ 13.9% |
| Current portion of amounts payable after more than one year42 | €53,443 | €101,054 | €80,167 | €86,788 | €82,891 | ▼ 4.5% |
| Financial debts43 | €442,530 | €547,814 | €598,959 | €507,131 | €482,042 | ▼ 4.9% |
| Credit institutions430/8 | €442,530 | €547,814 | €598,959 | €507,131 | €482,042 | ▼ 4.9% |
| Trade debts44 | €358,984 | €361,807 | €368,281 | €483,863 | €273,712 | ▼ 43.4% |
| Suppliers440/4 | €358,984 | €361,807 | €368,281 | €483,863 | €273,712 | ▼ 43.4% |
| Taxes, remuneration and social security45 | €308,443 | €463,579 | €397,259 | €288,933 | €337,988 | ▲ 17.0% |
| Taxes450/3 | €135,357 | €261,203 | €204,653 | €147,724 | €184,335 | ▲ 24.8% |
| Remuneration and social security454/9 | €173,086 | €202,376 | €192,606 | €141,209 | €153,654 | ▲ 8.8% |
| Other amounts payable47/48 | €218,573 | €30,945 | €0 | - | - | - |
| Accrued charges and deferred income492/3 | - | - | - | - | €998 | - |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €296,433 | €257,724 | €148,306 | €332,572 | €508,322 | ▲ 52.8% |
| + Depreciation and write-downs630 | €394,745 | €449,253 | €523,827 | €396,626 | €407,022 | ▲ 2.6% |
| Operating cash flow (approximation) | €691,177 | €706,976 | €672,133 | €729,198 | €915,344 | ▲ 25.5% |
| Investment in fixed assets (approximation) | - | -€580,142 | -€417,975 | -€436,559 | -€385,192 | ▲ 11.8% |
| Change in cash | - | -€36 | €2,014 | €20,263 | €170,564 | ▲ 742% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
17-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Highest result since 2018net €508,322 ▲52.8%
Operating result €618,658, net result €508,322, both a record.
31-12
Financial
Equity above €2mEq €2.5m ▲25.5%
5 profitable years in a row build equity to €2.5m.
25-08
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 25 days late
2024
31-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
13-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
18-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Back to profitnet €296,433
Net result €296,433 after one loss-making year.
14-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Weakest financial yearnet -€200,292
Net result drops to -€200,292, the lowest in the series; recovery starts the following year.
31-12
Financial
Equity above €1mEq €1.0m ▲351%
Equity rises from €228,060 to €1.0m.
29-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
Show earlier events
2019
31-12
Financial
Liquidity doublescurrent ratio 1.23
Current ratio from 0.54 to 1.23; short-term debt falls from €3.3m to €1.6m.
16-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
23-07
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
30-05
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 5 acts read
About the unread acts
We know of 5 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
5 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Turnhout · 1 establishment unit since 2008
Ground area
1.9 ha
Building footprint
4,569 m²
Volume, LiDAR
21,456 m³
Parcel 13453O0952/00E000, Flanders · tallest building 33.0 m, ±2 floors. Linked by address, not a title deed.
4
companies at this address
See who is registered here
1 establishment unit
Advanced Practical Diagnostics
since 20082.173.180.278
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 13453O0952/00E000 | Flanders | 1.9 ha | 1 · 4,569 m² | 33.0 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2022 to 2025 · 8 entries · 52,829 EUR awarded · 52,829 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 4 | 1,078 EUR | 51,078 EUR |
| 2024 | 2 | 51,017 EUR | 1,017 EUR |
| 2023 | 1 | 509 EUR | 509 EUR |
| 2022 | 1 | 225 EUR | 225 EUR |
European research
5 projects · 1,417,733 EUR EU contributionProgrammes
Projects
Immune Signatures for Therapy Stratification in Major Mood Disorders
Early diagnosis, treatment and prevention of mood disorders targetting the activated inflammatory response system
Brain Imaging Return to Health
Advanced Immuno-neuro-endocrine Diagnostics in Psychiatry
European Multicentre Tics in Children Studies
Similar companies · same sector, comparable size
White Raven
BE 0782.537.107
Liège · Eq €2,529,538
RevaTis
BE 0541.682.642
Marche-en-Famenne · Eq €2,551,321
VERBERT
BE 0462.345.847
Antwerpen · Eq €2,651,366
UniD Manufacturing
BE 0736.939.187
Seraing · Eq €2,668,980
V.M.D.
BE 0413.622.648
Arendonk · Eq €2,728,465
Of 148 companies in sector 21201 we hold annual accounts for 116. 66 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded18-09-2008
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
46460Wholesale of pharmaceutical and medical goods
32500Manufacture of medical and dental instruments and supplies
Scores and ratios are computed by Checked and are not a credit decision.